Represented Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) in its acquisitions of CyDex Pharmaceuticals, Inc., Verrow Pharmaceuticals, Inc., Metabasis Therapeutics, Inc. (Nasdaq: MBRX) and Neurogen Corporation (Nasdaq: NRGN); its acquisitions of over 30 third-party royalties/milestone payments streams from Selexis SA; its strategic alliances with Seelos Therapeutics and Nucorion Pharmaceuticals; and over 30 separate licensing arrangements with global and private pharmaceutical companies.
Represented KonaRed Corporation
in a $2.5 million growth capital financing. Santa-Monica-based Venice Brands, LLC
acted as the primary investor. The transaction involved two new series of convertible preferred stock, 23 different types of warrants, a mechanism for a contingent shift of power to elect a Board majority, two new stock option plans, a management transition with new services agreements, and KonaRed agreeing to “go dark” (elect to cease to be a reporting public company).
Harvard Law School, J.D., 1979, magna cum laude
Yale University, B.A., 1975, magna cum laude
Memberships & Associations
- Past President, San Diego County Bar Association